Genfit SA ( (GNFT) ) just unveiled an announcement.
On February 27, 2025, GENFIT announced its financial results for the year ending December 31, 2024. The company reported revenues of €67.0 million, a significant increase from €28.6 million in 2023, largely due to a €48.7 million milestone payment from Ipsen for the U.S. sale of Iqirvo® (elafibranor) for Primary Biliary Cholangitis. GENFIT’s cash position was €81.8 million, reflecting its ongoing R&D investments and strategic partnership with Ipsen. The company also secured a royalty financing deal for up to €185 million to support operations through 2027, contingent on bondholder approval and other conditions.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. The company is known for its pioneering work in liver disease research and has a diverse R&D portfolio targeting conditions such as Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma, urea cycle disorder, and organic acidemia. GENFIT also has a diagnostic franchise and is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA. It is listed on the Nasdaq Global Select Market and Euronext in Paris.
YTD Price Performance: -8.09%
Average Trading Volume: 8,255
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $184M
See more data about GNFT stock on TipRanks’ Stock Analysis page.